Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium

Leukemia

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study

Br J Haematol

Kunadt D, Zukunft S, Röllig C, Metzelder S, Burchert A, Wagner-Drouet E, Kriege O, Schliemann C, Stelljes M, Ronnacker J, Bethge W, Weller JF, Steffen B, Bug G, Kouidri K, Baldus C, Fransecky L, Sala E, Platzbecker U, Metzeler K, Kayser S, Hilgendorf I, Hochhaus A, Brümmendorf TH, Jost E, Doleschall AD, Schroeder T, Kaivers J, Kordelas L, Holtick U, Unglaub JM, Sauer T, Jäger PS, Kobbe G, Stauffer E, Tischer J, Herold T, Steiner N, Nachbaur D, Kröger N, Frietsch JJ, Kraus S, Einsele H, Hänel M, Schaffrath J, Krüger W, Brandenburg A, Holderried TAW, Reinhardt L, Maulhardt M, Thiede C, Bornhäuser M, Schetelig J, Middeke JM, Stölzel F, German Cooperative Transplant Study Group and Study Alliance Leukemia (SAL)

doi: 10.1111/bjh.70735

Leukemia

Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience

Br J Haematol

Chan WY, Al-Yousuf H, Lam HPJ, Leong S, Zheng J, Burt R, Wilson AJ, Xu K, Stringaris K, Alimam S, Raj K, Gupta R, Kottaridis P, Tailor A, Burgoyne R, Mansour MR, Khwaja A, Sellar R, Payne EM, O'Nions J

doi: 10.1111/bjh.70676

Lung, Respiratory and Thoracic Cancer

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Adv Ther

Sankar K, Unni S, Eberl M, Le H, Herrmann T, Gorsh B, Tang M, Coerts F, Ahmed S

doi: 10.1007/s12325-025-03408-z

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV

doi: 10.1016/j.esmoop.2025.106031

Leukemia

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

Am J Hematol

Molica M, Miralles G, Dillon R, Annunziata M, Basheer F, Bergua JM, Calmet FV, Campbell V, Cetin D, Cimino G, Ciotti G, Corbingi A, De Fazio L, Erol HA, Federico V, Gil C, Gulu YM, Malcorra AB, Mariani S, Mazzone C, Mulè A, Musuraca G, Khan A, Norata M, O'Nions J, Palumbo FE, Papayannidis C, Piccioni AL, Rubio MTO, Sanchez-Tovar J, Serin I, Serrao A, Sevindik OG, Sucato G, Urbano MA, Vetro C, Vives S, Rossi M, Martelli MP, Montesinos P, Othman J, Perrone S

doi: 10.1002/ajh.70142

Lung, Respiratory and Thoracic Cancer

First-line treatment for unresectable pulmonary lymphoepithelial carcinoma: A real-world comparison of platinum-based doublet chemotherapy with or without PD-1 inhibitors

Lung Cancer

Xue L, Feng Y, Chen P, Ye W, Cai X, Liang J, Zhou X, Li X, Li W, He J, Cheng B, Liang W

doi: 10.1016/j.lungcan.2026.109543

Lymphoma

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Br J Haematol

Villeneuve PJA, Mozessohn L, Somé NH, Mercer RE, Masucci L, Kouroukis T, Bredeson C, Aktar S, Guan Q, Prica A, Chen CI, Rodin D, Cheung M, Chaudhry M, Gavura S, McKay C, Wong WWL, Chan KKW

doi: 10.1111/bjh.70632

Leukemia

Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

Br J Haematol

Palmieri R, Piciocchi A, Soddu S, Frigeni M, Borlenghi E, Fracchiolla N, Martelli MP, Audisio E, Cignetti A, Gianfaldoni G, Vetro C, di Rienzo N, Esposito D, Di Veroli A, Selleri C, Gigli F, Curti A, Mulè A, Califano C, Bigliardi S, Breccia M, Fozza C, Bocchia M, Lico A, Simonetti F, Pierdomenico E, Marchetti M, Cerroni I, Buccisano F, Del Principe MI, Maurillo L, Paterno G, Fazi P, Vignetti M, Rossi G, Rambaldi A, Venditti A

doi: 10.1111/bjh.70752

Leukemia

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy

Haematologica

Watts J, Madarang E, Abbott D, Hart P, Sohalski C, Zoso A, Dell-Martin J, Belachew A, Amaya ML, Kent A, McMahon C, Schwartz M, Sekeres MA, Smith C, Bradley T, Taylor J, Chandhok N, Venugopal S, Jordan C, Berg M, Haag M, Willard N, Aisner D, Schowinsky J, Pan Z, Zhang J, Gutman JA, Pollyea DA

doi: 10.3324/haematol.2025.300374

Related content

Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study

Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience

Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients

First-line treatment for unresectable pulmonary lymphoepithelial carcinoma: A real-world comparison of platinum-based doublet chemotherapy with or without PD-1 inhibitors

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting

Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy